ERAS

ERAS is executing a textbook 'Post-Offering Breakout,' having successfully absorbed a $258M equity raise priced at $10.00/share on Jan 23, 2026. The +48% monthly surge was ignited by positive Phase 1 data for ERAS-0015 (pan-RAS molecular glue) released on Jan 12, creating a structural repricing event that defies the broader 'Tech Wreck.' While the general market is in CAUTION mode due to earnings volatility, the drop in 10-Year Treasury yields to 4.10% is acting as a massive tailwind for long-duration biotech assets like ERAS. The price action above $12.00 confirms that institutions are not just defending the $10.00 deal price but are actively accumulating, validating the 'Stealth Bull' rotation into high-quality idiosyncratic names.